ELISA/assay

Low Density Lipoprotein Receptor Related Protein 4 (LRP4) ELISA Kit

MBS2021747

48-Strip-Wells

565 USD

ELISA Kit

Low Density Lipoprotein Receptor Related Protein 4 (LRP4) ELISA Kit

Low Density Lipoprotein Receptor Related Protein 4 (LRP4)

MEGF7; LRP10; Multiple epidermal growth factor-like domains 7

low-density lipoprotein receptor-related protein 4; Low-density lipoprotein receptor-related protein 4; low-density lipoprotein receptor-related protein 4; low density lipoprotein receptor-related protein 4; Multiple epidermal growth factor-like domains 7

LRP4

LRP4; LRP4; CLSS; CMS17; LRP-4; LRP10; MEGF7; SOST2; KIAA0816; LRP10; MEGF7; LRP-4

LRP4_HUMAN

Human

1,905

This assay has high sensitivity and excellent specificity for detection of Low Density Lipoprotein Receptor Related Protein 4 (LRP4). No significant cross-reactivity or interference between Low Density Lipoprotein Receptor Related Protein 4 (LRP4) and analogues was observed.

For unopened kit: All the reagents should be kept according to the labels on vials. The Standard, Detection Reagent A, Detection Reagent B and the 96-well strip plate should be stored at -20 degree C upon receipt while the others should be at 4 degree C. For opened kit: When the kit is opened, the remaining reagents still need to be stored according to the above storage condition. Besides, please return the unused wells to the foil pouch containing the desiccant pack, and reseal along entire edge of zip-seal. The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Samples: Tissue homogenates, Cell lysates and other biological fluids. Assay Type: Sandwich. Detection Range: 0.313-20ng/mL. Sensitivity: Typically less than 0.126ng/mL.

Precision: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Low Density Lipoprotein Receptor Related Protein 4 (LRP4) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Low Density Lipoprotein Receptor Related Protein 4 (LRP4) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 . Intra-Assay: CV<10% . Inter-Assay: CV<12% . Assay Procedure Summary: 1. Prepare all reagents, samples and standards;. 2. Add 100uL standard or sample to each well. Incubate 2 hours at 37 degree C;. 3. Aspirate and add 100uL prepared Detection Reagent A. Incubate 1 hour at 37 degree C;. 4. Aspirate and wash 3 times;. 5. Add 100uL prepared Detection Reagent B. Incubate 30 minutes at 37 degree C;. 6. Aspirate and wash 5 times;. 7. Add 90uL Substrate Solution. Incubate 15-25 minutes at 37 degree C;. 8. Add 50uL Stop Solution. Read at 450nm immediately.

Principle of the Assay: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Low Density Lipoprotein Receptor Related Protein 4 (LRP4). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Low Density Lipoprotein Receptor Related Protein 4 (LRP4). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Low Density Lipoprotein Receptor Related Protein 4 (LRP4), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm 10nm. The concentration of Low Density Lipoprotein Receptor Related Protein 4 (LRP4) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

157384998

NP_002325.2

NM_002334.3

O75096

212,045 Da

ECM Proteoglycans Pathway (833812); Extracellular Matrix Organization Pathway (576262)

This gene encodes a member of the low-density lipoprotein receptor-related protein family. The encoded protein may be a regulator of Wnt signaling. Mutations in this gene are associated with Cenani-Lenz syndrome. [provided by RefSeq, May 2010]

LRP4: Mediates SOST-dependent inhibition of bone formation. Functions as a specific facilitator of SOST-mediated inhibition of Wnt signaling. Plays a key role in the formation and the maintenance of the neuromuscular junction (NMJ), the synapse between motor neuron and skeletal muscle. Directly binds AGRIN and recruits it to the MUSK signaling complex. Mediates the AGRIN- induced phosphorylation of MUSK, the kinase of the complex. The activation of MUSK in myotubes induces the formation of NMJ by regulating different processes including the transcription of specific genes and the clustering of AChR in the postsynaptic membrane. Alternatively, may be involved in the negative regulation of the canonical Wnt signaling pathway, being able to antagonize the LRP6-mediated activation of this pathway. More generally, has been proposed to function as a cell surface endocytic receptor binding and internalizing extracellular ligands for degradation by lysosomes. Defects in LRP4 are the cause of Cenani-Lenz syndactyly syndrome (CLSS). It is a congenital malformation syndrome defined as complete and complex syndactyly of the hands combined with malformations of the forearm bones and similar manifestations in the lower limbs. Defects in LRP4 are the cause of sclerosteosis type 2 (SOST2). A sclerosing bone dysplasia characterized by a generalized hyperostosis and sclerosis leading to a markedly thickened skull, with mandible, ribs, clavicles and all long bones also being affected. Due to narrowing of the foramina of the cranial nerves, facial nerve palsy, hearing loss and atrophy of the optic nerves can occur. Sclerosteosis is clinically and radiologically very similar to van Buchem disease, mainly differentiated by hand malformations and a large stature in sclerosteosis patients. Belongs to the LDLR family. Protein type: Cell surface; Receptor, misc.; Membrane protein, integral. Chromosomal Location of Human Ortholog: 11p11.2. Cellular Component: cell surface; cell soma; dendrite; postsynaptic density; integral to membrane; flotillin complex; neuromuscular junction. Molecular Function: protein binding; protein homodimerization activity; apolipoprotein binding; calcium ion binding; receptor tyrosine kinase binding. Biological Process: limb development; regulation of protein amino acid phosphorylation; extracellular matrix organization and biogenesis; Wnt receptor signaling pathway; dendrite morphogenesis; endocytosis; odontogenesis of dentine-containing teeth; hair follicle development; synaptic growth at neuromuscular junction; dorsal/ventral pattern formation; negative regulation of ossification; synapse organization and biogenesis; protein heterotetramerization; negative regulation of axonogenesis; embryonic digit morphogenesis; kidney development; proximal/distal pattern formation. Disease: Myasthenic Syndrome, Congenital, 17; Cenani-lenz Syndactyly Syndrome; Sclerosteosis 2

48-Strip-Wells

565 USD

96-Strip-Wells

765

5x96-Strip-Wells

2975

10x96-Strip-Wells

5340